Melatonin treatment in Alzheimer’s disease
Can melatonin treatment provide lasting benefits for memory and daily functioning in people with Alzheimer’s disease?
It can help readers distinguish evidence about brain structure and blood biomarkers from evidence that treatment improves patients’ lives.
Where it stands now
Main bottleneck
Current evidence identifies reviews and trials, including a three-month study of cerebellar structure and blood biomarkers, but does not establish whether melatonin produces sustained clinical benefits.
Watch next
Controlled trial results showing whether melatonin improves cognition or daily functioning, with safety and follow-up data sufficient to assess whether any benefit persists.
Progress timeline
How the evidence has changed over time.
2025 · 1 update
- How a planned 12-week melatonin comparison will measure sleep, memory, movement and blood markersResearch note 3 of 3 · Source date 2025-01-03
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: How a nighttime hormone might affect Alzheimer’s brain changes
Previous expectation: A tolerable melatonin regimen might help preserve everyday cognitive abilities if human research established meaningful sustained benefits and a suitable regimen.
What this study adds: NCT06756828 supplies a registered comparison of a specified melatonin regimen with sleep-hygiene education, using blood, cognitive, physical and sleep measures. The supplied record has no posted results, so it does not test the earlier forecast through reported outcomes.
Current research note
2024 · 2 updates
- Why timing changes the story of melatonin in Alzheimer’s diseaseResearch note 1 of 3 · Source date 2024-01-01
- How a nighttime hormone might affect Alzheimer’s brain changesResearch note 2 of 3 · Source date 2024-08-11
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: Why timing changes the story of melatonin in Alzheimer’s disease
Previous expectation: Earlier melatonin treatment might give people with early cognitive difficulties more time before further decline if longitudinal human research establishes benefit and a tolerable regimen.
What this study adds: The August 11, 2024 review connects multiple proposed biological mechanisms with reports of human cognitive and sleep outcomes and calls for pathology measurements to examine translation. It does not itself test the earlier forecast that treatment changes clinical progression.
Current research note
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.